![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Antengene’s ATG-101 Granted Orphan Drug Designation for Pancreatic Cancer
Antengene’s ATG-101 Granted Orphan Drug Designation for Pancreatic Cancer
Antengene’s ATG-101 has received an Orphan Drug designation by the FDA for treatment of patients with pancreatic cancer.
A bispecific antibody, ATG-101 is designed to block the binding of immunosuppressive PD-1/PD-L1 and to stimulate receptors that boost T cell activation.
The treatment aims to deliver enhanced antitumor activity with an improved safety profile, the company said.
ATG-101 could become the first PD-L1/4-1BB bispecific antibody approved for the treatment of pancreatic cancer, Antengene said.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct